Efficacy of Vitamin E in Preventing Contrast-Induced Acute Kidney Injury Following Coronary Angiography


The purpose of this study is to evaluate the effect of vitamin E on preventing from incidence of contrast induced acute kidney injury (CI-AKI) in the patients who undergone coronary angiography.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: May 2015


  • Drug: Vitamin E

Arms, Groups and Cohorts

  • Placebo Comparator: Placebo
  • Active Comparator: Vit-E
    • 600 IU on 12 hours before angiography and 400 IU on 2 hours before angiography

Clinical Trial Outcome Measures

Primary Measures

  • The development of CI-AKI in group receiving vitamin E compared with placebo
    • Time Frame: Within 72 hours after coronary angiography

Secondary Measures

  • Changes in the serum level of Cr and the amount of eGFR
    • Time Frame: Within 72 hours

Participating in This Clinical Trial

Inclusion Criteria

1. All patients whon have either stable coronary artery disease (CAD) or recent acute coronary disease (ACS) and are scheduled for coronary angiography.

2. Patients who have eGFR ≤60 ml/min/1.73 m2

Exclusion Criteria

1. Allergy to contrast media

2. Cardiogenic shock

3. Pulmonary edema

4. Overt cardiac failure or left ventricular ejection fraction ≤ 30%

5. Acute kidney injury

6. The history of receiving contrast media for any medical diagnostic or therapeutic procedures during previous 5 days

7. The history of dialysis

8. Being pregnant

9. Having recent acute myocardial infarction

10. Taking antioxidants and nephrotoxic drugs including NSAID and ACE-I on previous 2 days

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Urmia University of Medical Sciences
  • Provider of Information About this Clinical Study
    • Principal Investigator: Chancellor of research, Mir Hossein Seyyed-Mohammadzad – Urmia University of Medical Sciences

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.